Viz.ai is the latest company in the artificial intelligence space to draw attention from investors and raised about $21 million in a series A round.
Abbott Laboratories reported a strong second quarter overall, but in medical devices, the company appears to be losing share in cardiac rhythm management and neuromodulation. Could Abbott's loss in these markets be Medtronic or Boston Scientific's gain?
Through its new MiniMed 670G performance guarantee program, Medtronic said it will provide flat-fee reimbursements up to $25,000 per pump over four years of qualifying diabetes-related inpatient hospitalization and emergency room admissions for eligible in-network patients in the United States.
Baxter said it is evaluating other potential locations, including contract manufacturers, to support its supply needs if necessary.
The company asked the court to dismiss a negligence case involving St. Jude Medical's Riata ST lead, but a federal judge denied the motion, allowing the case to proceed.
Endologix promoted from within to fill the CEO seat. Will this strategy help the struggling EVAR company up its game?
MD+DI News Editor Amanda Pedersen talks about recent M&A trends in medtech and the attributes that make companies stand out as potential acquisition targets.
The San Francisco, CA-based company has raised $26.6 million in a series C round to help further commercialize its Accuryn Monitoring System.
Angiodynamics CEO Jim Clemmer assures investors that the company is ready and able to execute M&A opportunities, either in terms of divestitures or acquisitions.
At least one analyst sees a bright future for Nevro, even if the company is holding the short end of the stick at the conclusion of a longstanding patent dispute with Boston Scientific.
Verily and ResMed will form a joint venture to develop software solutions to identify and treat sleep apnea, as well as study the financial aspects of the disease if it goes undiagnosed and untreated.
Visura Technologies has received FDA clearance for a disposable camera that can help physicians view the upper airway during transesophageal echocardiogram (TEE) procedures.
Medtronic and UnitedHealthcare shared how a unique value-based partnership demonstrated a 27% decline in the rate of preventable hospital admissions for Medtronic insulin pump users compared to patients on multiple daily insulin injections.
Otsuka Holdings is set to acquire ReCor Medical for an undisclosed sum and follows Medtronic in a bid to get a renal denervation device on the market.